Medication reconciliation errors in the perioperative setting represent a critical concern for patient safety, with substantial implications for morbidity and mortality. This article reviews the epidemiology, pathophysiology, clinical manifestations, diagnostic approaches, and management strategies of surgical medication reconciliation errors, integrating recent evidence and guideline-based recommendations. Special emphasis is placed on the mechanisms underlying these errors, risk stratification, and the impact of emerging digital tools in mitigating adverse events, providing a practical synthesis for clinicians involved in perioperative care.
Medication reconciliation is the systematic process of creating the most accurate list possible of a patient’s current medications and comparing that list against the physician’s orders at every transition point within the hospital. In the surgical context, errors stemming from incomplete or inaccurate reconciliation can lead to adverse drug events (ADEs), procedural complications, and prolonged hospital stays. Given the complexity and high-risk nature of surgical care, robust medication reconciliation is essential for optimizing outcomes. This review addresses the scope, mechanisms, clinical impact, and evidence-based strategies to reduce medication reconciliation errors in the surgical setting, targeting a medical audience seeking to enhance perioperative safety standards.
Studies indicate that up to 67% of hospitalized patients experience at least one medication discrepancy during admission, transfer, or discharge, with surgical patients particularly vulnerable due to multiple care transitions. In the perioperative environment, the prevalence of reconciliation errors ranges from 20% to 60%, depending on patient complexity, institutional practices, and the rigor of reconciliation protocols. These errors contribute to an estimated 10-20% of surgical adverse drug events, resulting in increased morbidity, unplanned readmissions, and extended hospitalization. The economic burden is significant, with medication errors costing healthcare systems billions annually due to preventable complications and resource utilization.
Medication reconciliation errors in surgery arise from failures in communication, documentation, and clinical reasoning during transitions of care. Pathophysiologically, these errors can manifest as unintended omissions (e.g., abrupt cessation of antihypertensives), duplications, incorrect dosing, or inappropriate continuations of medications contraindicated perioperatively (e.g., anticoagulants, hypoglycemics). The interplay between altered pharmacokinetics in the perioperative period—due to fluid shifts, organ dysfunction, and anesthesia—can exacerbate drug toxicity or therapeutic failure. Disparities in electronic health records (EHRs), lack of interoperability, and time constraints further undermine comprehensive reconciliation, increasing the risk of iatrogenic harm.
Risk factors for surgical medication reconciliation errors encompass patient-level, provider-level, and system-level determinants. Polypharmacy, advanced age, cognitive impairment, language barriers, and complex comorbidities heighten susceptibility. Provider-related factors include inadequate training, high workload, and lack of standardized protocols. Systemic contributors involve fragmented communication between surgical, anesthetic, and nursing teams, inadequate EHR integration, and inconsistent policy enforcement. Emergency surgeries, frequent handoffs, and transitions between wards or institutions further amplify risk.
The clinical sequelae of reconciliation errors are diverse, ranging from minor symptoms to life-threatening complications. Omission of essential medications may precipitate hypertensive crises, arrhythmias, or seizure activity, while inappropriate continuation of agents such as anticoagulants or oral hypoglycemics can result in perioperative bleeding or severe hypoglycemia. Clinical features often overlap with postoperative complications, necessitating high clinical vigilance and multidisciplinary coordination. Early recognition is paramount, as delayed identification can lead to irreversible organ dysfunction or death.
Diagnosis of medication reconciliation errors relies on meticulous review of the patient’s medication history, surgical orders, and post-operative course. Structured medication history interviews, cross-referencing pharmacy records, and direct patient/caregiver engagement are integral. Discrepancy analysis, facilitated by clinical pharmacists, can highlight omissions, duplications, or dosing errors. Diagnostic vigilance is required in postoperative patients with unexplained clinical deterioration, bleeding, metabolic disturbances, or new neurologic symptoms, where reconciliation errors may be contributory.
Immediate management involves identification and correction of the medication error, risk stratification for potential adverse drug events, and prompt initiation of supportive measures. For omissions, reinstitution of critical medications (e.g., beta-blockers, anticonvulsants) is prioritized, whereas inappropriate continuations may require rapid de-escalation or administration of reversal agents (e.g., vitamin K for warfarin). Multidisciplinary collaboration—encompassing surgery, anesthesia, pharmacy, and nursing—is essential for coordinated care. Long-term strategies include standardized reconciliation protocols, use of checklists, and integration of clinical decision support systems within EHRs. Continuous education and feedback loops are vital for sustaining improvements.
Recent advances in health informatics have transformed medication reconciliation. Implementation of interoperable EHRs, automated reconciliation modules, and artificial intelligence-driven discrepancy alerts have shown promise in reducing errors. Mobile health (mHealth) platforms facilitate patient engagement and real-time medication updates. Pharmacist-led reconciliation at key transition points is supported by high-quality evidence, demonstrating reductions in ADEs and improved surgical outcomes. Ongoing research explores the utility of machine learning for risk prediction and the integration of genomic data to personalize perioperative drug choices, aiming to further enhance safety and efficacy.
Major organizations, including the Joint Commission and the World Health Organization, emphasize the critical importance of medication reconciliation across all care transitions. Key recommendations include performing medication reconciliation at admission, transfer, and discharge, involving patients and caregivers in the process, and employing multidisciplinary teams. Guidelines advocate for the incorporation of clinical pharmacists, utilization of standardized forms or electronic tools, and regular audit-feedback cycles. Tailoring protocols to local resources and patient populations is essential for successful implementation and sustainability.
Surgical medication reconciliation errors remain a prevalent and preventable source of perioperative morbidity and mortality. Recognition of at-risk populations, understanding the multifactorial mechanisms, and adherence to evidence-based protocols are critical for enhancing patient safety. Advances in digital health, interdisciplinary collaboration, and ongoing education offer tangible opportunities to reduce errors and optimize surgical outcomes. Continued research and system-level innovation are required to address persistent challenges and ensure the highest standards of perioperative medication management.
1.
Tumor characteristics found to differ for melanomas in children, teens and young adults
2.
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials
3.
"A lot" of aspirin reduces the risk of ovarian cancer, regardless of genetic factors, according to the JAMA study.
4.
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies
5.
Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?
1.
Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care
2.
Screening for Early Therapy-Related Cancer Susceptibility
3.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
4.
Skin-Sparing Mastectomy: Balancing Cancer Control with Cosmetic Results
5.
Reducing Modifiable Childhood Cancer Exposure Risks
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
3.
Should We Use DARA Up Front As First-Line Therapy in MM?
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
5.
Importance of Cancer Screening and Early Detection
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation